| Patent Number |
Title Of Patent |
Date Issued |
| D346562 |
Reflector |
May 3, 1994 |
|
| 7414067 |
Ophthalmic compositions for treating ocular hypertension |
August 19, 2008 |
| This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a |
| 7348348 |
Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers |
March 25, 2008 |
| Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically ac |
| 7326726 |
Biaryl substituted triazoles as sodium channel blockers |
February 5, 2008 |
| Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in c |
| 6632836 |
Carbocyclic potassium channel inhibitors |
October 14, 2003 |
| The present invention relates to a class of carbocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like. ##STR1## |
| 6545023 |
Cyclopentyl modulators of chemokine receptor activity |
April 8, 2003 |
| The present invention is directed to compounds of the formula I: ##STR1##(wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and X are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the |
| 6498165 |
Src kinase inhibitor compounds |
December 24, 2002 |
| Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and |
| 6489354 |
3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
December 3, 2002 |
| The present invention is directed to pyrrolidine compounds of the formula I: ##STR1##(wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4c, R.sup.4d, and R.sup.4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as mo |
| 6455548 |
4-alkyl piperidinyl pyrrolidine modulators of chemokine receptor activity |
September 24, 2002 |
| The present invention is directed to pyrrolidine compounds of the formula I: ##STR1##(wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4c, R.sup.4d, and R.sup.4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as mo |
| 6372764 |
Pyrrolidine modulators of chemokine receptor activity |
April 16, 2002 |
| The present invention is directed to pyrrolidine compounds of the formula I: ##STR1##(wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4c, R.sup.4d, and R.sup.4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as mo |
| 6362201 |
3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity |
March 26, 2002 |
| The present invention is directed to pyrrolidine compounds of the formula I: ##STR1##(wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4c, R.sup.4d, and R.sup.4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as mo |
| 6329380 |
SRC kinase inhibitor compounds |
December 11, 2001 |
| Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and |
| 6303637 |
Heterocyclic potassium channel inhibitors |
October 16, 2001 |
| The present invention relates to a class of heterocyclic compounds of Formula I that are useful as potassium channel inhibitors to treat autoimmune disorders, cardiac arrhythmias, and the like. ##STR1## |
| 6303593 |
3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity |
October 16, 2001 |
| The present invention is directed to pyrrolidine compounds of the formula I: ##STR1##(wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4c, R.sup.4d, and R.sup.4f are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as mo |
| 6194458 |
Benzamide potassium channel inhibitors |
February 27, 2001 |
| This invention relates to benzamide potassium channel inhibitors of general structural Formula I. ##STR1##The compounds of this invention are useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and related afflictions, diseases and |
| 6100293 |
Tetracyclic triterpene derivatives with immunosuppressant activity |
August 8, 2000 |
| The compounds of Formula I ##STR1## are useful as immunosuppressive agents. |
| 6083980 |
Furanyl, tetracyclic triterpene derivatives with immunosuppressant activity |
July 4, 2000 |
| The compounds of Formula I ##STR1## are useful as immunosuppressive agents. |
| 6051590 |
Immunosuppressant tricyclic compounds |
April 18, 2000 |
| The compounds of Formula I are useful as immunosuppressive agents. |
| 6022890 |
Immunosuppressant tetracyclic triterpenes |
February 8, 2000 |
| The compounds of Formula I ##STR1## are useful as immunosuppressive agents. |
| 5998408 |
Triterpene derivatives with immunosuppressant activity |
December 7, 1999 |
| The compounds of Formula I ##STR1## are useful as immunosuppressive agents. |
| 5952371 |
Triterpene derivatives with immunosuppressant activity |
September 14, 1999 |
| The compounds of Formula I ##STR1## are useful as iumnunosuppressive agents. |
| 5883119 |
Triterpene derivatives with immunosuppressant activity |
March 16, 1999 |
| The compounds of Formula I ##STR1## are useful as immunosuppressive agents. |
| 5874594 |
Triterpene derivatives with immunosuppressant activity |
February 23, 1999 |
|
| 5763478 |
Triterpene derivatives with immunosuppressant activity |
June 9, 1998 |
| The compounds of Formula I ##STR1## are useful as immunosuppressive agents. |
| 5696156 |
Triterpene derivatives with immunosuppressant activity |
December 9, 1997 |
| The compounds of Formula I ##STR1## are useful as immunosuppressive agents. |
| 5693648 |
O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity |
December 2, 1997 |
| Substituted compounds of the FK-506 Type. These compounds are useful for the same or essentially the same purposes as FK-506 and are applied in the same or a similar manner. These compounds are immunosuppressants and useful for the treatment of autoimmune diseases, infectious diseases |
| 5679705 |
Triterpene derivatives with immunosuppressant activity |
October 21, 1997 |
| The compounds of Formula I ##STR1## are useful as immunosuppressive agents. |
| 5670504 |
2,6-diaryl pyridazinones with immunosuppressant activity |
September 23, 1997 |
| A class of 2,6-diarylpyridazinones of general structural formula I have been identified that exhibit exhibit immunosuppressant activity with human T-lymphocytes, and are useful as an immunosuppressants. ##STR1## or a pharmaceutically acceptable salt, hydrate or crystal form thereof |
| 5565560 |
O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
October 15, 1996 |
| O-Aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian ho |
| 5550233 |
Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity |
August 27, 1996 |
| Aryl, alkyl, alkenyl and alkynyl macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by oxidation and alkylation at C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of |
| 5545734 |
Aryl and heteroaryl macrolides having immunosuppressive activity |
August 13, 1996 |
| Aryl and heteroaryl macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by olefination at C-27. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the preven |
| 5532248 |
O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity |
July 2, 1996 |
| O-Aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian ho |
| 5506262 |
Cholesterol lowering compounds |
April 9, 1996 |
| Disclosed herein are compounds of structural formula (I) ##STR1## which are useful as cholesterol lowering agents. These compounds are also useful as inhibitors of squalene synthetase, inhibitors of fungal growth, inhibitors of farnesyl-protein transferase and farnesylation of the |
| 5369125 |
Cholesterol-lowering agents |
November 29, 1994 |
| This invention relates to compounds of structural formula (I): ##STR1## which are squalene synthase inhibitors and thus useful as cholesterol lowering agents and antifungal agents. These compounds are also inhibitors of farnesyl protein transferase and farnesylation of the oncogene p |
| 5349061 |
O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having im |
September 20, 1994 |
| O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroaryl-macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosup |
| 5310903 |
Imidazolidyl rapamycin derivatives |
May 10, 1994 |
| Imidazolidyl rapamycin derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-42 and/or C-31. These compounds are useful in a mammalian host for the treatment of autoimmune diseases and diseases of inf |
| 5310901 |
O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives |
May 10, 1994 |
| O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylrapamycin derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-42 and/or C-31. These compounds are useful in a mammalia |
| 5258389 |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
November 2, 1993 |
| O-Aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-42 and/or C-31. These compounds are useful in a mammalian host for the treatment of autoimmu |
| 5254682 |
Cyclic renin inhibitors containing 3(S)-amino-4-cyclohexyl-2(R)-hydroxy-butanoic acid or 4-c |
October 19, 1993 |
| Compounds of the formula: ##STR1## are disclosed. These compounds inhibit the angiotensinogen-cleaving action of the natural proteolytic enzyme, renin, and are useful in treating, preventing or managing renin-associated hypertension, hyperaldosteronism, congestive heart failure, |
| 5252732 |
D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having im |
October 12, 1993 |
| O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppre |
| 5251115 |
Specific intensity distribution light reflector |
October 5, 1993 |
| A reflector for modifying the light intensity distribution patterns of a cylindrical light source has a first reflecting surface formed to provide a desired light intensity distribution pattern in the vertical plane and at least one other reflecting surface extending from one end of the |
| 5147867 |
Phosphorus containing enzyme inhibitors |
September 15, 1992 |
| Dipeptide mimics which contain phosphorus and their pharmaceutical use and preparation are disclosed. The compounds have dehydropeptidase (DHP) enzyme inhibitor activity. |
| 5145990 |
Phosphorous containing dhp enzyme inhibitors |
September 8, 1992 |
| Compounds of the formula: ##STR1## wherein R.sub.1 is C.sub.2- C.sub.12 linear or branched unsubstituted alkyl; C.sub.1- C.sub.12 linear or branched substituted alkyl; C.sub.2 -C.sub.12 linear or branched monoalkenyl; C.sub.2 -C.sub.12 linear or branched alkynyl; C.sub.7 -C.sub.2 |
| 5143908 |
Antibacterial agents and potentiators of carbapenem antibiotics |
September 1, 1992 |
| New 3-(1-aminoalkylphosphinyl)-(2-substituted)propionic acids are described which display antibacterial activity and potentiate carbapenem antibiotics. |
| 5099063 |
Certain phosphinic acid derivatives having antibacterial activity |
March 24, 1992 |
| New 3-(1-aminoalkylphosphinyl)-(2-substituted)propionic acids are described which display antibacterial activity and potentiate carbapenem antibiotics. |
| 5039664 |
Renin inhibitors containing phenylalanyl-histidine replacements |
August 13, 1991 |
| Peptides of the formula: ##STR1## which comprise novel elements replacing the Phe(8)-His(9) sequence in renin-inhibitory peptides based on substrate analogy, which inhibit the substrate-cleaving action of renin and have improved bioavailability; compositions containing these reni |
| 5037807 |
Renin inhibitors containing phenylalanyl-histidine replacements |
August 6, 1991 |
| Peptides of the formula: ##STR1## which comprise novel elements replacing the Phe(8)-His(9) sequence in renin-inhibitory peptides based on substrate analogy, which inhibit the substrate-cleaving action of renin and have improved bioavailability; compositions containing these reni |
| 4962097 |
Method of treating bacterial infection with phosphorus containing DHP enzyme inhibitors |
October 9, 1990 |
| Dipeptide mimics which contain phosphorus and their pharmaceutical use and preparation are disclosed. The compounds have dehydropeptidase (DHP) enzyme inhibitor activity. |
| 4873235 |
Benzofused lactams as antihypertensives |
October 10, 1989 |
| Benzofused lactams of the formula: ##STR1## and their use as angiotensin converting enzyme inhibitors and antihypertensive agents are disclosed. |
| 4839357 |
Renin inhibitors containing phenylalanyl-histidine replacements |
June 13, 1989 |
| Peptides of the formula: ##STR1## which comprise novel elements replacing the Phe(8)-His(9) sequence in renin-inhibitory peptides based on substrate analogy, which inhibit the substrate-cleaving action of renin and have improved bioavailability; compositions containing these reni |
